David Pickar
#127,494
Most Influential Person Now
David Pickar's AcademicInfluence.com Rankings
David Pickarengineering Degrees
Engineering
#4239
World Rank
#5424
Historical Rank
Robotics
#99
World Rank
#101
Historical Rank
Mechanical Engineering
#335
World Rank
#373
Historical Rank
Applied Physics
#986
World Rank
#1011
Historical Rank
Download Badge
Engineering
David Pickar's Degrees
- PhD Mechanical Engineering Stanford University
Why Is David Pickar Influential?
(Suggest an Edit or Addition)David Pickar's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. (1997) (1174)
- Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. (1986) (738)
- Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics (1997) (666)
- National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. (1991) (664)
- NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers (1996) (652)
- Cognitive effects of corticosteroids. (1990) (421)
- Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. (1997) (401)
- Neuropsychiatric effects of anabolic steroids in male normal volunteers. (1993) (392)
- Effort and cognition in depression. (1982) (390)
- Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. (1992) (364)
- Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. (1999) (353)
- Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. (1993) (335)
- Cognitive substrates of thought disorder, I: the semantic system. (1998) (321)
- Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. (1986) (318)
- The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia (1993) (309)
- Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers (1998) (301)
- Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study. (1988) (249)
- High plasma norepinephrine levels in patients with major affective disorder. (1982) (247)
- Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. (1984) (242)
- Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion (1997) (242)
- Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. (1988) (228)
- Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. (1991) (213)
- Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine (1997) (203)
- Controllable and uncontrollable stress in humans: alterations in mood and neuroendocrine and psychophysiological function. (1987) (196)
- No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. (1994) (187)
- Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. (1986) (185)
- Plasma norepinephrine level in affective disorders. Relationship to melancholia. (1985) (185)
- Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. (1999) (184)
- Early parental loss and development of adult psychopathology. (1988) (181)
- CSF corticotropin-releasing hormone in depressed patients and normal control subjects. (1987) (175)
- Positron Emission Tomography in Schizophrenic Patients with and without Neuroleptic Medication (1985) (173)
- The Relationship between Dorsolateral Prefrontal Neuronal N-Acetylaspartate and Evoked Release of Striatal Dopamine in Schizophrenia (2000) (168)
- Cerebral structural pathology in schizophrenia: evidence for a selective prefrontal cortical defect. (1988) (160)
- Neuroleptic responsivity of negative and positive symptoms in schizophrenia. (1987) (153)
- Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. (1987) (152)
- Surgical stress in humans is accompanied by an increase in plasma beta-endorphin immunoreactivity. (1981) (152)
- Elevated levels of soluble interleukin 2 receptors in schizophrenia. (1989) (149)
- Increased temporal lobe glucose use in chronic schizophrenic patients (1989) (140)
- Cognitive substrates of thought disorder, II: specifying a candidate cognitive mechanism. (1998) (140)
- Evidence for common alterations in cerebral glucose metabolism in major affective disorders and schizophrenia. (1989) (136)
- Dopamine D2 receptor density and personal detachment in healthy subjects. (1998) (134)
- Is the Mechanism of Prefrontal Hypofunction in Depression the Same as in Schizophrenia? (1993) (134)
- A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics (1998) (132)
- Cerebrospinal fluid opioid activity in anorexia nervosa. (1982) (131)
- Prednisone effects on neurochemistry and behavior. Preliminary findings. (1990) (124)
- Effects of the acute administration of caffeine in patients with schizophrenia (1990) (122)
- Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. (1996) (121)
- Prospects for pharmacotherapy of schizophrenia (1995) (121)
- Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia (1985) (118)
- Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia (1996) (110)
- Parental schizophrenia spectrum disorders in childhood-onset and adult-onset schizophrenia. (2003) (106)
- High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. (1983) (106)
- Are there two types of unipolar depression? (1975) (106)
- Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. (1994) (106)
- Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers (2003) (103)
- Symptoms and EEG Findings in the Borderline Syndrome (1986) (103)
- Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series. (1985) (102)
- Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study. (1982) (102)
- Neuropharmacological antagonism of the beta-carboline-induced "anxiety" response in rhesus monkeys (1985) (100)
- The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response (1998) (99)
- Clinical studies of the endogenous opioid system. (1982) (97)
- Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. (1990) (94)
- Increased numbers of CD5+ B lymphocytes in schizophrenic patients. (1989) (94)
- Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. (1986) (93)
- Attempted Suicide in Chronic Schizophrenia (1984) (91)
- Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. (1981) (91)
- Presnyaptic noradrenergic regulation during depression and antidepressant drug treatment (1980) (90)
- Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings. (1984) (86)
- In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia (2000) (85)
- Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. (1988) (83)
- Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. (2001) (83)
- Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. (1981) (81)
- Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. (1996) (80)
- Perspectives on a time-dependent model of neuroleptic action. (1988) (80)
- Clinical correlates of decreased anteroposterior metabolic gradients in positron emission tomography (PET) of schizophrenic patients. (1985) (79)
- Pharmacogenomics of psychiatric disorders. (2001) (78)
- Clozapine response and the 5HT2C Cys23Ser polymorphism (1996) (78)
- Effects of Acute Metabolic Stress on Striatal Dopamine Release in Healthy Volunteers (2000) (76)
- Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia (1998) (75)
- Naloxone administration in obsessive-compulsive disorder: report of two cases. (1983) (75)
- Chronic corticosterone administration in rats: behavioral and biochemical evidence of increased central dopaminergic activity. (1986) (75)
- Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls. Relationship to plasma cortisol levels before and after dexamethasone administration. (1987) (74)
- The effects of ceruletide in schizophrenia. (1984) (72)
- Autonomic effects of clozapine in schizophrenia: Comparison with placebo and fluphenazine (1993) (71)
- Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test. (1986) (70)
- The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. (1997) (69)
- Diazepam-induced amnesia: a neuropharmacological model of an "organic amnestic syndrome". (1987) (69)
- Adverse Effects of Antipsychotic Drugs (1993) (68)
- Plasma cortisol and beta-endorphin immunoreactivity in nonmajor and major depression. (1984) (68)
- BEHAVIOURAL EFFECTS AFTER HIGH DOSE NALOXONE ADMINISTRATION TO NORMAL VOLUNTEERS (1981) (68)
- Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. (1987) (67)
- Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers (1988) (66)
- 5HT2a receptor T102C polymorphism and schizophrenia (1996) (65)
- CSF GABA in depressed patients and normal controls (1989) (65)
- Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use (2008) (64)
- Clinical and biochemical effects of verapamil administration to schizophrenic patients. (1987) (64)
- Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia (1994) (62)
- SURGICAL STRESS AND ENDORPHINS (1981) (62)
- Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. (1996) (62)
- Increased serum soluble interleukin-2 receptors in caucasian and Korean schizophrenic patients (1994) (62)
- Spectrum of EEG abnormalities during clozapine treatment. (1994) (62)
- The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. (1988) (61)
- Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping (1984) (61)
- ALTERED PAIN PERCEPTION AND CEREBROSPINAL ENDORPHINS IN PSYCHIATRIC ILLNESS (1982) (60)
- Episodic secretion of opioid activity in human plasma and monkey CSF: evidence for a diurnal rhythm. (1981) (60)
- Verapamil concentrations in cerebrospinal fluid after oral administration. (1985) (60)
- CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients. (1986) (58)
- Stress-induced plasma beta-endorphin immunoreactivity may predict postoperative morphine usage (1982) (57)
- Physiological effects of high dose naloxone administration to normal adults. (1982) (57)
- Maladaptive anticipatory saccades in schizophrenia (1991) (57)
- Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia (1994) (56)
- Mechanism of Peripheral Noradrenergic Stimulation by Clozapine (1998) (56)
- Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. (1986) (55)
- CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide (1985) (55)
- Supression of plasma cortisol in depressed patients by acute intravenous methadone infusion. (1980) (54)
- Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. (1993) (54)
- CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers (1997) (53)
- Addressing ethical issues in the psychiatric research literature. (1999) (53)
- Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls (1986) (53)
- Methadone and morphine in depression (1981) (52)
- Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. (1993) (52)
- Co-release of ACTH and beta-endorphin immunoreactivity in human subjects in response to central cholinergic stimulation. (1983) (50)
- Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. (1987) (50)
- Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. (1990) (50)
- Predictors of clozapine response in schizophrenia. (1994) (48)
- High-dose naloxone affects task performance in normal subjects (1983) (48)
- Expressed Emotion Trait or State? (1995) (48)
- Cerebrospinal fluid corticotropin-releasing hormone in depression: Relationship to noradrenergic function (1987) (48)
- Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans (1992) (47)
- Idazoxan, an ??2 Antagonist, Augments Fluphenazine in: Schizophrenic Patients (1993) (47)
- Abnormalities in the Distributed Network of Sustained Attention Predict Neuroleptic Treatment Response in Schizophrenia (1998) (46)
- Primary affective disorder, clinical state change, and MHPG excretion: a longitudinal study. (1978) (46)
- Plasma norepinephrine responses to cold challenge in depressed patients and normal controls (1987) (45)
- Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. (1989) (45)
- Dexamethasone increases plasma HVA but not MHPG in normal humans (1985) (44)
- Life events in depression. Relationship to subtypes. (1985) (44)
- The corticotropin-releasing hormone stimulation test in chronic schizophrenia. (1986) (43)
- In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine (1999) (43)
- Autonomic activity in relation to symptom ratings and reaction time in unmedicated patients with schizophrenia (2005) (43)
- Correlation of Wisconsin Card Sorting Test performance with eye tracking in schizophrenia. (1991) (42)
- PLASMA OPIOID ACTIVITY IN MANIC-DEPRESSIVE ILLNESS (1980) (42)
- Lack of gender differences in neuroleptic response in patients with schizophrenia (1996) (42)
- Cerebrospinal fluid monoamine and monoamine metabolite levels and the dexamethasone suppression test in depression. Relationship to life events. (1986) (41)
- Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients (1984) (41)
- Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients. (1985) (40)
- A quantitative analysis of smooth pursuit eye tracking in monozygotic twins discordant for schizophrenia. (1997) (40)
- Ethanol increases opioid activity in plasma of normal volunteers. (1981) (38)
- Plasma norepinephrine in chronic schizophrenia. (1990) (38)
- Topographic differences between normals and schizophrenics: the N120 evoked potential component. (1986) (37)
- Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. (1982) (36)
- Pre- and post-dexamethasone plasma ACTH levels in depressed patients and normal controls. (1986) (36)
- Neurobiologic Correlates (1986) (36)
- Methadone and morphine in depression [proceedings]. (1981) (35)
- Animal models of self-destructive behavior and suicide. (1985) (34)
- Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine. (1989) (34)
- The role of the endogenous opioid system in the human stress response. (1983) (34)
- Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). (1998) (33)
- Steroid modulation of human memory: Biochemical correlates (1993) (32)
- Course of Illness and Predictors of Outcome in Chronic Schizophrenia: Implications for Pathophysiology (1992) (32)
- The effects of dexamethasone on plasma homovanillic acid and 3-methoxy-4-hydroxyphenylglycol. Evidence for abnormal corticosteroid-catecholamine interactions in major depression. (1987) (32)
- Repeated naloxone administration in schizophrenia: A phase II world health organization study (1989) (31)
- The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness (1991) (31)
- Pain enhances naloxone-induced hyperalgesia in humans as assessed by somatosensory evoked potentials (2004) (31)
- Cerebral structure in borderline personality disorder (1989) (31)
- Suicidal behavior in depression: Relationship to noradrenergic function (1989) (29)
- High dose naloxone in depression. (1984) (29)
- Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients (1993) (29)
- Diazepam‐binding inhibitor and corticotropin‐releasing hormone in cerebrospinal fluid (1989) (29)
- Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. (1989) (28)
- Dopaminergic and peptidergic mRNA levels in juvenile rat brain after prenatal cocaine treatment. (1994) (28)
- The relationship of plasma cortisol and beta-endorphin immunoreactivity to surgical stress and postoperative analgesic requirement. (1983) (28)
- Single-dose naloxone acutely reduces eating in obese humans: Behavioral and biochemical effects (1988) (28)
- Dextroamphetamine infusions in normals result in correlated increases of plasma beta-endorphin and cortisol immunoreactivity. (1981) (28)
- Morphological brain abnormalities in schizophrenia determined by computed tomography: A problem of measurement? (1987) (27)
- Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness. (1987) (27)
- Tyramine pressor sensitivity changes during deprenyl treatment (2004) (27)
- Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia. (1990) (27)
- Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins (2005) (27)
- REM sleep suppression induced by selective monoamine oxidase inhibitors (2004) (27)
- Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia: A Comparison with Clozapine and Placebo (2002) (26)
- ENDORPHINS IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS (1982) (26)
- Thyrotropin releasing hormone test in unipolar depressed patients and controls: Relationship to clinical and biologic variables (1988) (26)
- Naloxone effects on β-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers (2004) (26)
- Serum antibodies to Epstein-Barr virus in patients with major depressive disorder. (1986) (25)
- Biologic tests in depression. (1984) (25)
- The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. (1991) (25)
- Neuroendocrine and personality variables in dysthymic disorder. (1985) (25)
- Hormonal effects of high dose naloxone in humans (1985) (24)
- Dr. Amsterdam and Associates Reply (1982) (24)
- Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA (1989) (24)
- Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers (1981) (23)
- Apolipoprotein E ε4 and clinical phenotype in schizophrenia (1997) (23)
- Suicidal Behavior in Chronic Schizophrenic Patients: A Follow-up Study (1986) (23)
- The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia: Evidence of a Sex Effect (1999) (22)
- Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. (1993) (21)
- Urinary-free cortisol in depressed patients and controls: relationship to urinary indices of noradrenergic function (1988) (21)
- Prolactin response to beta-endorphin in man. (1980) (21)
- Tyramine infusions and selective monoamine oxidase inhibitor treatment (2004) (20)
- High-dose naloxone administration in chronic schizophrenia (1985) (20)
- Algorithms for the treatment of schizophrenia. (1995) (20)
- The Effects of Cholecystokinin‐like Peptides in Schizophrenics and Normal Human Subjects (1985) (19)
- Relative activity of metabolic pathways for norepinephrine in endogenous depression (1986) (18)
- Effect of naloxone on food consumption in obesity. (1985) (18)
- Neuroleptics, dopamine, and schizophrenia. (1986) (17)
- Pharmacogenomics of psychiatric drug treatment. (2003) (17)
- NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES DE LA TOURETTE SYNDROME (1978) (17)
- Effects of Atypical Antipsychotic Drug Treatment on Amphetamine-Induced Striatal Dopamine Release in Patients with Psychotic Disorders (1999) (16)
- D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients. (1997) (16)
- Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia (1986) (16)
- Assay of endogenous opiate receptor ligands in human CSF and plasma. (1980) (15)
- Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. (2003) (15)
- A search for interferon in the CSF of chronic schizophrenic patients. (1985) (15)
- Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man (1981) (15)
- Drug trials and heterogeneity in schizophrenia: The mean is not the end (1990) (15)
- Behavioral change in a cancer patient following intrathecal beta-endorphin administration. (1984) (15)
- Informed consent in schizophrenia research. (1998) (14)
- Pharmacological challenges to the endogenous opioid system in affective illness. (1981) (14)
- Effect of carbamazepine on CSF opioid activity: Relationship to antidepressant response (1981) (14)
- Specificity of plasma HVA response to dexamethasone in psychotic depression (1989) (14)
- Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. (1982) (14)
- The Apolipoprotein E ε4 Allele Is Associated with Blunting of Ketamine-Induced Psychosis in Schizophrenia: A Preliminary Report (1998) (14)
- High intercorrelations among urinary outputs of norepinephrine and its major metabolites. A replication in depressed patients and controls. (1988) (14)
- Myoclonus-associated hypomania during MAO-inhibitor treatment. (1980) (13)
- Extreme elevations in plasma norepinephrine associated with decreased alpha-adrenergic responsiveness in major depressive disorder: two case reports. (1983) (13)
- Clinical investigation of monoamine neurotransmitter interactions (2005) (13)
- Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat (1985) (13)
- Tardive dyskinesia in younger patients. (1978) (12)
- Pharmacologic profile of natural products used to treat psychotic illnesses. (1995) (12)
- Tyramine infusions and selective monoamine oxidase inhibitor treatment (2004) (12)
- Amphetamine-Induced Dopamine Release and Post-Synaptic Specific Binding in Patients with Mild Tardive Dyskinesia (2001) (12)
- Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. (1997) (11)
- Clinical response to clozapine in patients with schizophrenia. (1994) (11)
- Prednisone-induced behavioral and biological changes in medically healthy volunteers. (1988) (11)
- Allelic variation in the promoter region of the dopamine D2 receptor gene influences the antipsychotic response to clozapine (1998) (11)
- Metabolic stress effects in normal volunteers and schizophrenic patients. (1988) (11)
- Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. (1997) (11)
- A Controlled Magnetic Resonance Imaging Study (2016) (11)
- Neuroleptic effects on autonomic activity in schizophrenia: between-group and within-subject paradigms and comparisons with controls. (2001) (11)
- A new algorithm for treating schizophrenia. (1998) (10)
- Lithium Potentiation of Imipramine in Treatment Resistant Depression (1985) (10)
- Tyramine infusions in bipolar illness: behavioral effects and longitudinal changes in pressor sensitivity. (1979) (10)
- Studies of the Endogenous Opioid System in the Human Stress Response (1986) (10)
- A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid (1988) (10)
- Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients (1982) (9)
- Diazepam-induced amnesia: a neuropharmacological model ofan ???organicamnesic syndrome??? (1987) (9)
- Clozapine treatment of schizophrenia. (1995) (9)
- Steady‐state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia (1988) (9)
- The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. (1998) (9)
- Urinary excretion of free tyramine and of norepinephrine and its metabolites in unipolar depressed patients (1986) (9)
- Diazepam binding inhibitor and corticotropin releasing hormone in cerebrospinal fluid (1989) (9)
- Quantitative electroencephalographic correlates of steroid administration in man. (1993) (8)
- The measurement of endorphins in body fluids. (1983) (8)
- Prednisone effects on blood-brain barrier permeability and CNS IgG synthesis in healthy humans (1990) (8)
- Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia (1990) (8)
- Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man (1992) (8)
- Behavioral and physiological responses to benzodiazepine receptor antagonists. (1984) (7)
- CLINICAL AND EXPERIMENTAL STUDIES OF STRESS AND THE ENDOGENOUS OPIOID SYSTEM (1982) (7)
- Neurochemistry and neuropharmacology. (1988) (7)
- Characteristics of patients selected for treatment on a schizophrenia research unit. (1990) (7)
- Measurement of endorphins in CSF. Relationship to psychiatric diagnosis. (1981) (7)
- Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration (1990) (7)
- Measurement of Endorphins in CSF (1981) (6)
- Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics (1989) (6)
- Endorphins and Affective Illness (1982) (6)
- Effects of psychotropic drugs on neurotransmitters in man. (1987) (6)
- Normal ventricles and sulci in schizophrenic patients (1983) (6)
- TRH test in schizophrenic patients and controls (1989) (6)
- 51. D2 Receptor occupancy in risperidone and clozapine-treated schizophrenics (1996) (5)
- Aggression during drug-free and antipsychotic treatment in inpatients with chronic schizophrenia, using the overt aggression scale (1995) (5)
- Increased percentages of T lymphocytes in the CSF of schizophrenic patients (1991) (5)
- TRH-induced prolactin release in unipolar depressed patients and controls. (1988) (5)
- A clinical perspective on microdialysis (1990) (5)
- Predicting Response to Clozapine (1999) (5)
- The D2 receptor: love it and leave it (1998) (5)
- Metabolic stress produces rapid immunosuppression in humans. (1987) (5)
- Profiles of the pharmacologic response of positive and negative symptoms in schizophrenia. Comment (1987) (4)
- Dr. Wolkowitz and Dr. Pickar Reply (1992) (4)
- Computed tomography measurements of brain density in schizophrenia (1991) (4)
- Alterations in noradrenergic function during clorgyline treatment. (1980) (4)
- Implications of monoamine oxidase inhibitor-induced hypomania. (1978) (4)
- Cardiovascular changes accompanying MAO inhibition in man (1981) (4)
- Striatal dopamine D2 receptor occupancy in patients treated with olanzapine (1998) (4)
- Opioidergic and dopaminergic gene expression in the caudate-putamen and accumbens of the mutant mouse, tottering (tg/tg). (1997) (4)
- D2 occupancy and dopamine release determined by 123I-IBZM spect following clozapine dose reduction (1995) (4)
- Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients. (1987) (4)
- Biologic Predictors of Clozapine Response in Schizophrenia (1996) (4)
- Dr. Wolkowitz and Associates Reply (1986) (3)
- REGIONAL BRAIN METABOLISM AS PREDICTORS OF CLOZAPINE RESPONSE (1992) (3)
- NALOXONE IN SCHIZOPHRENIA (1983) (3)
- Hospital vs. community. (1993) (3)
- Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. (1997) (3)
- ROLE OF OPIOID PEPTIDES IN DISORDERS OF ATTENTION IN PSYCHOPATHOLOGY (1982) (3)
- Dr. Kaye and Associates Reply (1983) (2)
- 157 Characterization of inbred mouse strain differences in startle and the prepulse inhibition model of schizophrenia (1997) (2)
- Long-term Outcome in Chronic Schizophrenia-Reply (1992) (2)
- Self-reported cognitive impairment predicts patient preference between risperidone and clozapine (1995) (2)
- Physiological Effects of High Dose Naloxone Administration to Normal Adults (1983) (2)
- 48. Assessment of striatal dopamine function in schizophrenia (1996) (2)
- 460. Proton magnetic resonance spectroscopic imaging in drug free patients with schizophrenia: Regional neuronal damage (1996) (2)
- MHPG Excretion-Reply (1979) (2)
- Response of plasma cortisol and β-endorphin immunoreactivity to surgical stress (1982) (2)
- 296. NMDA receptor function and schizophrenia: Studies with ketamine (1996) (2)
- Alprazolam augmentation of neuroleptics in schizophrenia. (1989) (2)
- Effects of clozapine on cognition in patients with schizophrenia (1991) (1)
- 5HT 2a receptor T102C polymorphism and schizophrenia. (1996) (1)
- URINARY 3-METHOXY-4-HYDROXYPHENETHYLENE GLYCOL AND STATE VARIABLES IN AFFECTIVE DISORDER (1979) (1)
- [Endorphins and endogenous psychoses]. (1984) (1)
- 415. Effects of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia (1998) (1)
- The effects of treatment with antipsychotics on N-acetylaspartate measures in patients with schizophrenia (2000) (1)
- Neuroanatomical localization of NMDA receptor-mediated psychosis in healthy controls and schizophrenic patients (1995) (1)
- Cerebrospinal Fluid and Behavioral Changes After Methyltestosterone Administration (2015) (1)
- New strategies for treating psychosis. (1996) (1)
- 278. A comparison of ketamine-induced and schizophrenic thought disorder (1998) (1)
- Alprazolam-neuroleptic treatment in schizophrenia (1989) (1)
- 608 The NMDA receptor and schizophrenia: From phenotype to genotype (1997) (1)
- The effects of neuroleptic dose adjustment on D2 receptor occupancy and schizophrenic symptomatology, a study using IBZM spect (1994) (1)
- A follow-up neurobiological study: why volunteer? (1979) (1)
- A trial of micelamide in schizophrenia (1989) (1)
- Augmentation of neuroleptics with idazoxan: Focus on noradrenergic function in schizophrenia (1993) (1)
- Smooth pursuit eye tracking in monozygotic twins discordant for schizophrenia (1994) (1)
- PLASMA HOMOVANILLIC ACID AND OTHER PREDICTORS OF CLOZAPINE RESPONSE (1992) (1)
- 604 The Effects of clozapine on plasma norepinephrine kinetics in schizophrenic patients (1997) (1)
- Pharmacotherapy of schizophrenia (1995) (1)
- Positive and Negative Symptoms of Schizophrenia (1986) (1)
- Differential effects of clorgyline on noradrenergic vs serotonergic systems in man (1982) (1)
- 41. Familial schizophrenia spectrum disorders in childhood-and adult-onset schizophrenia (2000) (0)
- Alprazolam Augmentation of Antipsychotic Pharmacotherapy?-Reply (1989) (0)
- Subjective Conclusions About Schizophrenia-Reply (1992) (0)
- The Prevalence of Schizophrenia in the US (2018) (0)
- Predictors of outcome in schizophrenia (1989) (0)
- 494. Neuroendocrinological impacts of glucoprivic stress (1996) (0)
- 240 Lack of association between 5HT2A, 5HT2C, and D4 receptor gene polymorphisms and the deficit syndrome of schizophrenia (1997) (0)
- Measuring dbi like immunoreactivity of human cerebro spinal fluid (1985) (0)
- 612 Predicting clozapine response: Systematic evaluation of allelic variation in candidate genes (1997) (0)
- Regional cerebral blood flow during sinusoidal pursuit, fixation and saccadic eye movements in patients with schizophrenia and normal controls (1993) (0)
- 354. The effects of metabolic and cognitive stress on cerebral blood flow (1996) (0)
- SUBJECTIVE CONCLUSIONS ABOUT SCHIZOPHRENIA. AUTHOR'S REPLIES (1992) (0)
- The cognitive effects of ketamine, an NMDA antagonist, in normal controls and drug-free schizophrenic patients (1995) (0)
- Effects of typical and atypical neuroleptics on plasma and urinary monoamine metabolites (1989) (0)
- The industrialization of pharmacogenomics for psychiatric disorders (2000) (0)
- Regionally specific changes in brain glucose metabolism association with response to clozapine treatment (1995) (0)
- Systeme a base pharmacogenomique pour mise en application clinique (2002) (0)
- Putting a Face on Serious Mental Illness (2017) (0)
- Challenges in patient management (1998) (0)
- Suggestive evidence for a quantitative trait locus on chromosome 3 for prepulse inhibition in the mouse (1998) (0)
- Clozapine for Treatment of Schizophrenia-Reply (1996) (0)
- Subject Index Vol. 27, 1993 (1993) (0)
- Augmentation of Response to Typical Neuroleptic Treatment Using Idazoxan, an Alpha-2 Antagonist, in Patients with Schizophrenia (1994) (0)
- Mental illness, violence and the gun control debate: evidence, policy, privacy and stigma-on behalf of the ACNP Ethics Committee (2013) (0)
- Report of Two Cases (1983) (0)
- The biochemical basis for the antipsychotic effects of neuroleptics (1987) (0)
- Neuroanatomical localization of ketamine-induced psychosis in schizophrenic patients and controls (1994) (0)
- Clozapine treatment in patients with chronic schizophrenia: efficacy and predictors of response (1994) (0)
- Effects of fluphenazine on plasma homovanillic acid: Central or peripheral origins? (1985) (0)
- Clinical and biological effects of clozapine in schizophrenic patients (1991) (0)
- Norepinephrine and metabolites in CSF, plasma, and urine in depression (1989) (0)
- In vivo estimates of synaptic dopamine concentrations with 11C-raclopride/pet: A direct test of the dopamine hypothesis (1995) (0)
- Contents of The American Journal of Psychiatry (1987) (0)
- The role of gender in the pharmacotherapy of schizophrenia (1995) (0)
- 443. Dextroamphetamine-induced neurochemical effects in chronic schizophenics and healthy volunteers (1998) (0)
- A time-dependent model of neuroleptic action (1988) (0)
- 498 Assessment of synaptic dopamine concentrations in schizophrenia with pet (1997) (0)
- Testing pathophysiologic hypotheses of psychiatric illness by molecular genetic approaches (1995) (0)
- The mechanism of action of clozapine: Implications for a new generation of antipsychotics (1995) (0)
- Clozapine response and allelic variation in the 5HT2A and 5HT2C receptor genes (1996) (0)
- Aggression in the treatment of inpatients with schizophrenia, using the overt aggression scale (1995) (0)
- Stress effects on norepinephrine and endogenous opioid peptides in human plasma (1981) (0)
- Neuropsychological specificity and schizophrenia: A comparison with affective groups (1993) (0)
This paper list is powered by the following services:
